ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.720 -0.210 (-2.11%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

There May Still Be Time to Get in on These 3 Trending Biotechs

January 20, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Via MarketBeat

Topics ETFs Economy

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 ↗

January 13, 2025

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Via Investor's Business Daily

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

January 13, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

How Is The Market Feeling About ADMA Biologics? ↗

December 30, 2024

Via Benzinga

Looking Into ADMA Biologics's Recent Short Interest ↗

December 05, 2024

Via Benzinga

SpringWorks Therapeutics Stock Gets A RS Rating Lift ↗

January 08, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Via Investor's Business Daily

ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

January 07, 2025

From ADMA Biologics, Inc.

Via GlobeNewswire

Arcellx Stock Earns 82 Relative Strength Rating ↗

December 27, 2024

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Via Investor's Business Daily

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

December 20, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

(ADMA) - Analyzing ADMA Biologics's Short Interest ↗

October 22, 2024

Via Benzinga

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

December 13, 2024

Via ACCESSWIRE

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations

December 12, 2024

Via ACCESSWIRE

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

BioNTech Stock Got A IBD RS Rating Lift ↗

November 14, 2024

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Via Investor's Business Daily

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

November 12, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable. ↗

November 12, 2024

For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering.

Via Chartmill

Vericel Stock Sees RS Rating Shoot Higher ↗

November 11, 2024

The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.

Via Investor's Business Daily

Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation

November 09, 2024

From Kirby McInerney LLP

Via Business Wire

ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update

November 07, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)

November 05, 2024

From Kirby McInerney LLP

Via Business Wire

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm

November 05, 2024

From The Schall Law Firm

Via Business Wire

Buckle Up And Use Volitility To Your Advantage ↗

November 03, 2024

The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary.

Via Talk Markets

What You Missed On Wall Street This Past Friday ↗

November 03, 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday ↗

November 01, 2024

Via Benzinga

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle ↗

November 01, 2024

The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.

Via Investor's Business Daily

ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

October 29, 2024

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm

October 29, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm

October 28, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.